fimaporfin
Small moleculeexperimental
Amphinex is a photosensitising agent used in photodynamic therapy for treating superficial cancers. — Wikipedia
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00993512)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Photosensitiser
Generates reactive oxygen molecules
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAmphinex ↗
- ChEMBLCHEMBL4297882 ↗
Also known as
- amphinex
- amphinex
- fimaporfin
- fimaporfin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04099888 | Phase 2 | May 23, 2019 | PCI Biotech AS |
| NCT02947854 | Phase 1 | Sep 1, 2016 | Covance, PCI Biotech AS |
| NCT01900158 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | PCI Biotech AS, University of Liverpool |
| NCT01606566 | Phase 2 | Apr 1, 2012 | Netherlands Cancer Institute, PCI Biotech AS |
| NCT01872923 | Phase 1 | Jan 1, 2012 | PCI Biotech AS, University of London |
| NCT00993512 | Phase 1 | Aug 1, 2009 | PCI Biotech AS, University of London |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PCI Biotech AS | For profit | 6 | 6 | 2 | 2009 |
| University of London | Academic/Hospital | 2 | 0 | 1 | 2009 |
| Covance | For profit | 1 | 0 | 1 | 2016 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Liverpool | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1